1977
Risk of new cancers in patients with Hodgkin's disease
Arseneau J, Canellos G, Johnson R, Devita V. Risk of new cancers in patients with Hodgkin's disease. Cancer 1977, 40: 1912-1916. PMID: 907993, DOI: 10.1002/1097-0142(197710)40:4+<1912::aid-cncr2820400823>3.0.co;2-d.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseAcute nonlymphocytic leukemiaNew cancersActive Hodgkin's diseaseLong-term complicationsSecond malignant tumorsReports of casesNational Cancer InstituteDirect cellular damageSynergistic carcinogenic effectPotential contributory factorsFurther immunosuppressionUntreated patientsImmunologic abnormalitiesTerm complicationsImproved survivalHD patientsImmunosuppressive factorsNonlymphocytic leukemiaMalignant diseaseMalignant tumorsCancer InstitutePatientsCytotoxic drugsTherapeutic interventions
1971
Studies on the Anti-Tumor Action of Poly I: Poly C
Levy H, Adamson R, Carbone P, DeVita V, Gazdar A, Rhim J, Weinstein A, Riley F. Studies on the Anti-Tumor Action of Poly I: Poly C. 1971, 55-65. DOI: 10.1007/978-3-642-85772-0_5.Peer-Reviewed Original Research
1970
Pentamidine: Clinical pharmacologic correlations in man and mice
Waalkes T, Denham C, DeVita V. Pentamidine: Clinical pharmacologic correlations in man and mice. Clinical Pharmacology & Therapeutics 1970, 11: 505-512. PMID: 5310706, DOI: 10.1002/cpt1970114505.Peer-Reviewed Original ResearchConceptsDiffuse interstitial pneumoniaInterstitial pneumoniaUrinary excretionPlasma levelsPneumocystis cariniiSingle intraperitoneal injectionTypes of pneumoniaDosage scheduleCancer patientsMalignant diseaseRenal abnormalitiesConcomitant useIntraperitoneal injectionIntramuscular administrationOrgan transplantationExcretion patternsPatientsPneumoniaPentamidineExcretionDrugsMenDiseaseMiceCarinii